Exonate adds Dr. Rafiq Hasan to its Board as Non-Executive Director

– USA, MA –  Exonate Ltd., a biotechnology company developing novel, non-invasive, small-molecule therapeutics for patients with retinal vascular diseases, today announced the addition of Dr. Rafiq Hasan to its Board as Non-Executive Director, bringing extensive expertise in ophthalmology, specifically within the diabetic eye disease sector, from his years in global pharmaceutical businesses.

About Dr. Rafiq Hasan

Dr. Rafiq Hasan has a proven record of success in the global pharmaceutical industry and is currently CEO of Complement Therapeutics, which focuses on developing next-generation complementary medicines. In addition to his role at Complement, he holds Board and advisory roles at Oxular and BioGeneration Ventures. Previous leadership roles within the ophthalmology sector have included SVP and Global Head of Ophthalmology at Bayer, where he oversaw the launch of Eylea® for five indications within three years, and from launch to >$2.5 billion in five years.

Dr Rafiq Hasan commented: “Exonate’s lead candidate is extremely promising, with the potential to transform treatments options for diabetic eye disease by alleviating the need for repeated, invasive injections into the eye. I look forward to working with Catherine and the team to help guide the Company’s continued success.”

SOURCE: https://www.exonate.com/

- DisclaimerNews, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.